Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
An AI biology platform has identified five promising therapeutic targets for Alzheimer's disease by analyzing the NAD⁺-mitophagy axis — a key pathway in brain aging and neurodegeneration. The study, published in Alzheimer's & Dementia, found that molecular changes in these pathways appear early in disease progression and may even be detectable via blood tests, opening the door to earlier diagnosis and new treatments.
A new study published in Alzheimer's & Dementia is turning heads in the neuroscience world. Researchers from Insilico Medicine, the University of Oslo, and Akershus University Hospital used an AI-driven biology platform called PandaOmics to analyze gene expression across 12 brain regions, cerebrospinal fluid, and blood — comparing healthy aging with four major neurodegenerative diseases: Alzheimer's, Parkinson's, Huntington's, and ALS.
The team zeroed in on the NAD⁺-mitophagy axis — a cellular pathway critical for mitochondrial health and energy metabolism — and found that disruptions in this system are present early in disease progression. Crucially, some of these molecular changes were detectable in blood samples, suggesting potential for non-invasive early biomarkers. PandaOmics evaluated over 100 candidate genes and prioritized five therapeutic targets for Alzheimer's: ULK1, OPA1, LAMP2, MFN1, and ATP6V0E1. Lab experiments confirmed the AI's predictions — boosting OPA1 activity improved cell survival and reduced toxic Tau buildup, while silencing MFN1 and LAMP2 worsened it.
Key Takeaways:
Why it matters: Drug discovery for Alzheimer's has long been a challenging space with a high rate of trial failures. This AI-plus-wet-lab approach offers a faster, more targeted path to identifying therapies — and the blood biomarker angle could transform how early we catch the disease.
